Skip to main content

Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study



Breast cancer incidence is increasing rapidly in Latin America, with a higher proportion of cases among young women than in developed countries. Studies have linked inflammation to breast cancer development, but data is limited in premenopausal women, especially in Latin America.


We investigated the associations between serum biomarkers of chronic inflammation (interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), leptin, adiponectin) and risk of premenopausal breast cancer among 453 cases and 453 matched, population-based controls from Chile, Colombia, Costa Rica, and Mexico. Odds ratios (OR) were estimated using conditional logistic regression models. Analyses were stratified by size and hormonal receptor status of the tumors.


IL-6 (ORper standard deviation (SD) = 1.33 (1.11–1.60)) and TNF-α (ORper SD = 1.32 (1.11–1.58)) were positively associated with breast cancer risk in fully adjusted models. Evidence of heterogeneity by estrogen receptor (ER) status was observed for IL-8 (P-homogeneity = 0.05), with a positive association in ER-negative tumors only. IL-8 (P-homogeneity = 0.06) and TNF-α (P-homogeneity = 0.003) were positively associated with risk in the largest tumors, while for leptin (P-homogeneity = 0.003) a positive association was observed for the smallest tumors only.


The results of this study support the implication of chronic inflammation in breast cancer risk in young women in Latin America. Largest studies of prospective design are needed to confirm these findings in premenopausal women.

Peer Review reports


Breast cancer is the most frequently diagnosed cancer worldwide and the leading cause of cancer death among women [1]. However, the age distribution of the cases varies geographically, with 12% of estimated breast cancer cases occurring in women younger than 45 years old in high-income countries, in contrast to 20% in Latin America [1]. This higher percentage of cases in young women in Latin America can only partially be explained by the different age structure of the population, and rather suggests that some risk factors, or the distribution of breast cancer subtypes, are characteristic of this population [2]. However, very few studies have been conducted so far to investigate the etiology of premenopausal breast cancer specifically in Latin America [3].

Obesity is associated with a decreased risk of breast cancer in premenopausal women in different populations worldwide [4], including in Latin American women [5, 6]. This inverse association is not well understood but may be associated to different metabolic phenotypes imperfectly captured by generic anthropometric measures, with varying degrees of excess body fat, dyslipidemia, insulin resistance, elevated blood pressure, and systemic low-grade inflammation [7, 8].

Systemic inflammation is a known correlate of obesity, as macrophages become the largest cell population in obese adipose tissue, resulting in altered expression of pro- or anti-inflammatory cytokines in the circulation [9]. In addition, increased fat mass is associated with altered production of adipokines [10], of which leptin and adiponectin are the most studied. These two peptides, produced by the adipose tissue, have various biological functions, including the regulation of satiety [10], and may be involved in insulin resistance [9].

Tight links exist between inflammation and the development of different cancers, including breast cancer [11]. A meta-analysis of 12 prospective studies conducted mostly in Caucasian women and focusing on C-Reactive protein (CRP), a non-specific marker of acute inflammation, showed a positive association with breast cancer risk [12]. However, only two studies were conducted in premenopausal women, with inconsistent findings [13, 14]. Studies considering biomarkers of chronic inflammation remain limited, in particular in young women [15]. To our knowledge, only one prospective study reported associations between inflammatory markers such as cytokines and breast cancer risk in premenopausal women [16], showing contrasting results in associations, while most of the studies published so far on this topic were mainly of clinical settings and relatively small sample sizes.

In this work, we examined associations between seven serum biomarkers of inflammation (interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), tumor necrosis factor α (TNF-α), interferon γ (IFN-γ) and adipokines (leptin and adiponectin) and breast cancer risk in premenopausal women from Latin America, using data from the multicentric PRECAMA population-based case–control study.



PRECAMA is an ongoing multicentric population-based case–control study based in Chile, Colombia, Costa Rica, Mexico, and Brazil [17,18,19]. Information on lifestyle, health and reproductive history was collected at recruitment. Standardized protocols were used to collect biological samples (fasting blood, spot urine) and anthropometric measures (height, weight, waist and hip circumferences) at the time of interview. Immunohistochemistry analyses on tumor tissue for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK5/6) was performed centrally at the Fred Hutchinson Cancer Research Center in Seattle. Tumour samples with ≥ 1% immunostained tumour cell nuclei were considered positive (ER positive (ER +), PR positive (PR +)). For HER2, samples were considered positive if there was strong membrane immunostaining (3 +).

All participants gave written informed consent before enrolment, and the study protocols were approved by the local institutional review and the International Agency for Research on Cancer (IARC).

Selection of cases and controls

Cases were women diagnosed with first primary incident breast cancer in general or cancer-specific hospitals or private oncology institutes [19], recruited before receiving any treatment, who fulfilled the following inclusion criteria: 1) age 20–45 years; 2) being resident for ≥ 3 years in the same city district; 3) having an incident primary invasive breast cancer with positive biopsy and clinical staging; 4) having menstruated at least once in the past 12 months.

Controls were selected from the general population residing in the same city district as the case for at least 3 years using a multilevel sampling frame [19]. Controls were matched to cases on age (± 3 years), city district of residence, and health insurance institution.

Participants from Brazil were not included in the present work as the recruitment started later.

A total of 453 cases and 453 controls were included in the present analysis.

Biological specimens’ collection and analysis

Biological specimens were collected according to standardized protocols [19,20,21]. Blood samples were obtained at recruitment, prior to any treatment, by venipuncture using vacutainers aliquoted into serum, plasma, red blood cells, and buffy coat and stored at -80 °C. Half of the aliquots were stored locally in each center while a mirror half was centralized and stored at IARC.

Laboratory measurements of IL-6, IL-8, IL-10, TNF-α, IFN-γ, leptin, and adiponectin were performed on serum samples at IARC (Biomarkers Group) using a highly sensitive and specific multiplexing electro-chemiluminescent assay (V‐PLEX™ Custom Human Cytokine Kit, Meso Scale Discovery, Rockville, MD). The laboratory technician who performed assays was blind to case–control status of the samples. Samples from cases and matched controls were analyzed in the same analytical batch. Three quality control samples were included in duplicate in each batch of analyses. Overall within-batch coefficients of variations ranged from 2.9% for IFN-γ to 9.7% for IL-6. Between-batch CVs ranged from 5.7% for adiponectin to 11.4% for IFN-γ. For each biomarker, values below the lower limit of quantification were imputed to this lower limit (n = 6 for IL-6; n = 44 for IL-10; n = 7 for TNF-α; n = 40 for IFN-γ) while values above the upper limit of quantification were imputed to this upper limit (n = 6 for leptin).

All cases and controls included in the study had available measurements for IL-6, IL-10, TNF-α, IFN-γ, and adiponectin, while leptin was available only for 860 subjects (430 case–control pairs), and IL-8 on 628 subjects (314 case–control pairs).

Statistical analysis

Population’s characteristics were described using frequency for categorical variables, and arithmetic mean and standard deviation for continuous variables, except for biomarker concentrations which were described using geometric means.

In all following analyses, concentrations of biomarkers were log-transformed to approximate normal distribution and we used residuals of log-transformed variables regressed on analytical batch as exposures of interest. For covariates, missing values represented less than 5% of values and were imputed to the mode (parity) or to the median (waist circumference, hip circumference, height, weight, BMI, use of hormones at blood collection, and, among parous women only, age at first full-term pregnancy). Triple-negative (TN) tumors were defined as ER-negative, PR-negative, and HER2-negative. Among the TN tumors, basal-like tumors were defined as ER-negative, PR-negative, HER2-negative, and EGFR-positive (EGFR +) and/or CK5/6-positive (CK5/6 +).

Spearman's partial correlation coefficients between concentrations of inflammation markers (as residuals of log-transformed variables regressed on analytical batch) and anthropometric factors and age were calculated among controls, adjusting for age (except for correlations with age).

Odds ratios (ORs) for risk of breast cancer and their associated 95% confidence intervals (CI) were estimated using conditional logistic regression models. Concentrations of biomarkers and leptin/adiponectin ratio (residuals of log-transformed variables on analytical batch) were examined as continuous variables (OR estimated per standard deviation increment) and in quartiles, defined on the distributions of control participants. Tests for linear trends across quartiles were computed by assigning all individuals in a quartile the median value of the biomarker in this quartile and considering this variable as a continuous variable in the model. Potential non-linear associations were modelled using restricted cubic splines (3 knot), and BMI-adjusted models were compared by likelihood ratio test.

We considered four models for each biomarker. First, we evaluated associations in a model including only matching variables. Second, we evaluated a model adjusted for BMI (continuous). Third, we examined a model adjusted for waist circumference (continuous) instead of BMI, as these variables are highly correlated but reflect different types of adiposity. Eventually, to rule out confounding originating from other variables than BMI and waist circumference, we examined a model adjusted for the following breast cancer risk factors: BMI (continuous), age at menarche (years, continuous), number of full-term pregnancies (0/1/2/ ≥ 3), age at first pregnancy (nulliparous, tertiles), breastfeeding duration (nulliparous, tertiles), use of hormones at blood collection (yes/no), personal history of benign breast disease (yes/no), family history of breast cancer in first-degree relatives (yes/no), smoking status (ever smoker/never smoker), alcohol consumption (g/day), moderate physical activity (hours/day), education level (up to primary school/secondary school/longer than secondary school), and adult height (continuous).

In cases for whom the information was available, analyses were stratified according to immunohistochemistry results for ER, PR, and HER2 (298 pairs, ER-positive, ER-negative, triple-negative) and tumor size (N = 311 pairs, ≤ 2 cm/2–5 cm/ > 5 cm). All models in stratification were adjusted for BMI only, since sample size was too limited in subgroups to run the fully adjusted model. We additionally stratified analysis by BMI (< 25/ ≥ 25 kg/m2; < 30/ ≥ 30 kg/m2), using logistic regression analyses adjusted for matching factors. We assessed heterogeneity by including an interaction term between the variable used for stratification and the biomarker of interest.

We conducted a sensitivity analysis excluding women using exogenous hormones at inclusion (n = 86 women, leading to exclusion of 74 case–control pairs).

All statistical tests were two-sided. All analyses were performed using R Studio Version 1.2.5042 and R version 4.0.3.


On average, cases were aged 38.8 at inclusion (38.7 in controls) and in the 298 cases with available immunohistochemistry data, 72.1% of tumors were ER-positive, 68.8% were PR-positive, and 14.1% were triple-negative (Table 1). Characteristics of the cases by hormone receptor status are shown in Supplementary Table 1 (see Additional File 1).

Table 1 Main characteristics of study population by case/control status

Compared with controls, cases were more likely to be nulliparous (18.1% versus 7.5%). Parous cases were on average older at their first full-term pregnancy (23.9 years versus 21.9 years) and breastfed less (41.8% did not breastfed or breastfed less than 8 months (first tertile) versus 26.0%) than parous controls. Cases had more frequently a history of benign breast disease (36.4% versus 12.1%) and a level of education above secondary school (37.1% versus 24.5%) than controls. Compared with controls, cases had a lower BMI (26.4 kg/m2 versus 29.2 kg/m2), waist circumference (91.0 cm versus 94.5 cm), and hip circumference (103.5 cm versus 106.5 cm).

Age-adjusted Spearman correlation coefficients among control participants were moderate between circulating levels of different cytokines (IL-6, IL-8, IL-10), TNF-α, and IFN-γ (0.13 ≤ r ≤ 0.41) (Fig. 1). In addition, IL-6 was positively correlated with leptin (r = 0.36) and the leptin/adiponectin ratio (r = 0.42), negatively correlated with adiponectin (r = -0.23), and showed stronger correlations with anthropometric measures than with biomarkers (0.47 with BMI, 0.44 with waist circumference, 0.44 with hip circumference). Leptin showed the strongest positive correlations with BMI, waist and hip circumferences (respectively 0.52, 0.49, and 0.47) and leptin/adiponectin ratio (respectively 0.57, 0.53, and 0.49), while adiponectin showed negative correlations with BMI, waist and hip circumferences (respectively -0.25, -0.22, and -0.19). Correlations between waist-hip ratio and biomarkers were lower than with other anthropometric measures (0.12 ≤|r|≤ 0.22). Weak correlations were also seen between TNF-α and anthropometric measures (0.10 to 0.17).

Fig. 1
figure 1

Age-adjusted Spearman correlation coefficients between concentrations* of inflammation markers and anthropometric measures among control participants. *Concentration of biomarkers as residual of log-transformed variables regressed on analytical batch. Only statistically significant correlations (P-value < 0.05) are shown. Bold indicate negative correlation coefficients. Abbreviations: BMI body mass index; IFN interferon, IL interleukin; OR odds ratio; SD standard deviation; TNF tumor necrosis factor

In the model including only matching factors (Table 2), no significant associations were observed for interleukins, TNF-α, and IFN-γ with breast cancer risk, while leptin and leptin/adiponectin ratio showed significant negative associations (leptin: ORper SD increment (95% CI) = 0.76 (0.66–0.87), ORQ4vsQ1 = 0.48 (0.33–0.70), P-trend < 0.001; leptin/adiponectin ratio: ORper SD increment = 0.75 (0.65–0.86), ORQ4vsQ1 = 0.53 (0.36–0.79), P-trend < 0.001). A positive but borderline statistically significant association was also observed for adiponectin (ORper SD increment = 1.14 (0.99–1.31); ORQ4vsQ1 = 1.45 (0.98–2.14), P-trend = 0.04).

Table 2 Associations between inflammatory biomarkers and breast cancer risk in premenopausal women from the PRECAMA study

After adjustment for BMI, associations between leptin, adiponectin and leptin/adiponectin ratio and breast cancer risk were no longer significant, while a significant positive association was observed for IL-6 (ORper SD increment = 1.32 (1.12–1.55); ORQ4vsQ1 = 1.55 (1.04–2.30), P-trend = 0.01).

When adjusting the univariate model for waist circumference, instead of BMI, the association of IL-6 and breast cancer risk was attenuated (ORper SD increment = 1.24 (1.07–1.44); ORQ4vsQ1 = 1.32 (0.90–1.95), P-trend = 0.06). In the same waist circumference-adjusted model, IL-8 was positively associated with risk (ORper SD increment = 1.15 (0.98–1.36); ORQ4vsQ1 = 1.59 (1.01–2.52), P-trend = 0.07). Leptin and leptin/adiponectin ratio were negatively associated with breast cancer risk when adjusting for waist circumference, although associations were attenuated as compared with the univariate model.

In the fully adjusted model (which included BMI but not waist circumference), IL-6 was positively associated with breast cancer risk (continuous variable only, ORper SD increment = 1.33 (1.11–1.60)), as was TNF-α (ORper SD increment = 1.32 (1.11–1.58); ORQ4vsQ1 = 2.03 (1.26–3.26), P-trend = 0.006). A significant positive association was observed for IL-8 in quartiles (ORQ4vsQ1 = 2.16 (1.14–4.07), P-trend = 0.06), but not for the continuous variable (ORper SD increment = 1.15 (0.93–1.44)). Borderline negative associations were observed for leptin (ORper SD increment = 0.82 (0.67–1.00)) and leptin/adiponectin ratio (ORper SD increment = 0.81 (0.66–1.00)). No associations were observed overall for IL-10 and IFN-γ.

Although no departure from linearity was suggested from the linear trend test across quartiles, natural cubic spline models indicated evidence for non-linearity for IL-6 (P-value = 0.03) and TNF-alpha (P-value = 0.04) (Supplementary Fig. 1, see Additional File 1), but not for other biomarkers (all P-values ≥ 0.30).

When stratifying analyses by tumor immunohistochemistry (Fig. 2), IL-8 was observed to be positively associated with breast cancer risk for ER-negative tumors only (ER-positive: ORper SD increment = 0.95 (0.72–1.24); ER-negative: ORper SD increment = 1.73 (0.98–3.06); P-homogeneityER+ vs ER- = 0.05). In contrast, a negative association was observed for IFN-γ in ER + tumors only (ORper SD increment = 0.82 (0.67–1.00), although the test for heterogeneity for receptor status was not significant (P-homogeneityER+ vs ER- = 0.14). No evidence of heterogeneity was observed for other biomarkers (all P-homogeneity > 0.23) or when comparing triple-negative to non-triple-negative tumors (all P-homogeneity > 0.12).

Fig. 2
figure 2

Associations between inflammatory biomarkers and breast cancer, by estrogen receptor status and in triple-negative tumors. Odds ratios are per standard deviation increase in residuals of log-transformed biomarker concentration regressed on analytical batch, estimated from conditional logistic regression models adjusted for BMI. P-homogeneity ER compares estrogen receptor negative and positive tumors. P-homogeneity TN compares triple-negative and non-triple-negative tumors. Abbreviations: BMI body mass index, CI confidence interval, ER + estrogen receptor positive, ER- estrogen receptor negative, IFN interferon, IL interleukin, OR odds ratio, SD standard deviation, TN triple negative, TNF tumor necrosis factor

When exploring associations by tumor size, little evidence of heterogeneity was observed for IL-6 and breast cancer risk (Fig. 3, P-homogeneity = 0.90), although significant associations were observed only in tumors <  = 2 cm and 2–5 cm (< = 2 cm: ORper SD increment = 1.63 (1.09–2.44); 2-5 cm: ORper SD increment = 1.43 (1.01–2.02) but not for larger tumors (> 5 cm: ORper SD increment = 1.17 (0.85–1.61)).

Fig. 3
figure 3

Associations between inflammatory biomarkers and breast cancer risk, by tumor size. Odds ratios are per standard deviation increase in residuals of log-transformed biomarker concentration regressed on analytical batch, estimated from conditional logistic regression models adjusted for BMI. Abbreviations: BMI Body mass index, CI Confidence interval, IFN Interferon, IL Interleukin, OR Odds ratio, SD Standard deviation, TN Triple negative, TNF Tumor necrosis factor.

For IL-8 and TNF-α, a significant positive association was observed only for the largest tumors (IL-8: ORper SD increment = 1.88 (1.12–3.15), P-homogeneity = 0.06; TNF-α: ORper SD increment = 1.58 (1.10–2.26), P-homogeneity = 0.003). Leptin and adiponectin were positively associated with risk in smaller tumors (leptin: ORper SD increment = 1.56 (1.07–2.28); adiponectin: ORper SD increment = 1.37 (0.99–1.89)), with P-homogeneity = 0.03 for both biomarkers), while negative associations were observed for larger tumors, only significant for leptin in tumors of 2 to 5 cm (ORper SD increment = 0.66 (0.45–0.97)).

When stratifying analyses on BMI using 25 kg/m2 as a cut-off, no interaction between BMI and any of the biomarkers was observed (all P-interaction > 0.40, not shown). However, when using a cut-off of 30 kg/m2, a significant interaction with IL-8 (P-interaction = 0.03; < 30 kg/m2: ORper SD increment = 1.06 (0.88–1.28); ≥ 30 kg/m2: ORper SD increment = 1.49 (1.05–2.15)), and a borderline significant interaction with TNF-α (P-interaction = 0.05; < 30 kg/m2: ORper SD increment = 1.08 (0.93–1.26); ≥ 30 kg/m2: ORper SD increment = 1.42 (1.05–1.95)) were observed. When restricting the analysis to women not using exogenous hormones, associations remained unchanged, except for a positive association between IL-8 and breast cancer risk overall in all multivariate models (BMI-adjusted: ORper SD increment = 1.22 (1.01–1.48); WC-adjusted: ORper SD increment = 1.22 (1.02–1.46); fully adjusted: ORper SD increment = 1.46 (1.13–1.90), not tabulated).


This analysis of seven inflammatory biomarkers and breast cancer risk in a case–control study in premenopausal women from Latin America showed that IL-6 and TNF-α were positively associated with breast cancer risk when accounting for adiposity and other breast cancer risk factors. While the association with IL-6 was consistent across different breast cancer subtypes and tumor sizes, the association with TNF-α was limited to larger tumors. A positive association was observed for IL-8 in ER-negative and in larger tumors, and in hormones non-users at blood donation, while a negative association was observed for IFN-γ in ER-positive tumors only. Leptin and leptin/adiponectin ratio showed negative associations with breast cancer risk in univariate models, that were attenuated when adiposity was accounted for. When associations were explored by tumor size, however, negative associations were observed in larger tumors (> 2 cm) and positive associations in smaller tumors.

The positive association between IL-6 and breast cancer risk is in line with the only prospective study of biomarkers of chronic inflammation and risk of premenopausal breast cancer we identified [16]. In this study among Italian women, a positive association was reported between circulating IL-6 levels and breast cancer risk independently from overall adiposity. In addition, several cross-sectional studies [22,23,24] have shown higher circulating IL-6 concentrations in breast cancer patients than in controls, as often reported for cancer patients overall [25, 26]. However, menopausal status of these women was not specified in these studies, and adjustment for obesity was not considered. As well, these studies reported increasing IL-6 concentrations with increasing disease stage [22,23,24]. However, in the present work, IL-6 associations with breast cancer risk did not vary by tumor size. Mechanistic studies suggest a complex role of IL-6 in cancer development, with effects at both local and systemic levels, mainly mediated through the JAK/STAT3 signaling pathways [26, 27]. Stimulation of the IL-6 / JAK / STAT3 pathway in cancer cells modulates the expression of several genes involved in the proliferation, survival and transformation of tumor cells [27]. Activation of this pathway is also suggested to decrease anti-tumor immunity by creating an immunosuppressive tumor microenvironment [27].

IL-8 concentrations were previously reported to be higher in breast cancer cases than in healthy women [24, 28], with higher concentrations in ER-negative than ER-positive tumors [24], defining IL-8 as a possible marker of ER-negative and/or HER2-positive breast cancers [29]. This may rely on a close crosstalk between IL-8 and ER expression in breast tissue [29, 30]. However, it has been shown that IL-8 can increase invasiveness of breast cancer cells, irrespective of their ER status [29], for instance by promoting angiogenesis [31]. It has also been shown that highly metastatic cell lines produce more IL-8 than lower metastatic cell lines [32], which may support the association we reported in this study showing an association only for the largest tumors. This is also in line with previous studies reporting increased concentrations of IL-8 among patients with metastatic disease [28]. The observation of a positive association only when hormone users were excluded could result from a potential influence of oral contraceptive use on inflammatory markers, although not specific to IL-8 [33]. Another possible explanation is that oral contraceptive users are at increased risk for breast cancer [34], and this association may mask the association with IL-8.

IL-10 is known to be an anti-inflammatory cytokine reported to have mostly anti-tumor properties, based on experimental and clinical data, but pro-tumor actions have sometimes been reported based on in vitro and animal studies [35]. Higher levels of serum IL-10 have also been reported in breast cancer patients as compared to controls [23], but we did not detect any association in this work, for all cancers, nor by receptor expression, or by tumor size.

Our finding of a positive association between TNF-α and breast cancer is consistent with several case–control studies showing higher serum TNF-α concentrations in breast cancer patient than controls [24, 36,37,38,39]. These studies however were not focused on premenopausal women only. Furthermore, concentrations of TNF-α have been seen to correlate with several disease characteristics [39]. One study [24] indicated that the difference in TNF-α concentrations between breast cancer patients and controls was significant only for stage III cancers, consistent with the positive association that we observed only for large tumors. The only prospective study analyzing the association between TNF-α and breast cancer risk in premenopausal women showed a positive association across tertiles of TNF-α (P-trend = 0.02) [16]. This pro-inflammatory cytokine is suspected to be involved in tumor progression and metastasis but its role in breast cancer remains challenging to understand, as results from studies on breast cancer-derived cell lines indicate that TNF-α may actually induce either apoptosis or cell proliferation, depending on the cellular context [39, 40].

IFN-γ has anti-tumor properties, i.e., pro-apoptotic, anti-angiogenic, and promotor of anti-tumor immune response [41], that are in line with the negative association we observed in our study. The few studies we identified exploring the association between IFN-γ and breast cancer risk in breast cancer patients versus controls (unspecified menopausal status) suggested either no difference [42] (250 aged-matched case–control pairs) or lower concentrations in cases [43] (29 controls, 55 patients not receiving chemotherapy, 32 receiving chemotherapy).

It is not clear why in our study we observed a significant association in ER-positive tumors only. However, since the heterogeneity between tumors with different estrogen receptors was not statistically significant, the observed difference in association could result from a lack of statistical power in the ER-negative subgroup.

In the present work, leptin was inversely associated with breast cancer risk in both univariate and fully adjusted model, however this association lost significance when the univariate model was adjusted for BMI. Leptin is a pro-inflammatory adipokine [44] strongly positively associated with BMI. Since we reported a strong inverse association between BMI and breast cancer in this population [6], the negative association between leptin and breast cancer may result from residual confounding. However, our results are consistent with an Italian prospective study [16] reporting a negative association in premenopausal women, even when BMI was considered. As well, two additional prospective studies [45, 46] reported negative associations, although they did not reach statistical significance in the fully adjusted model. When stratifying analysis by tumor stage or in situ versus invasive, the latter studies [45, 46] reported negative associations in the less advanced tumors, which contrasts with our observation of a positive association in the smallest tumors. In line with results on leptin, leptin/adiponectin ratio, a suggested marker of insulin resistance [47], was also negatively associated with breast cancer risk in the present work.

We did not observe any association of adiponectin with breast cancer risk, consistent with findings from three prospective studies in premenopausal women [16, 45, 48] and two case–control studies [49]. Baseline data from a randomized controlled trial, in which premenopausal women with intraepithelial neoplasia or micro-invasive breast cancer were compared to healthy high-risk women (5-year Gail score > 1.3%), showed a decrease in risk with increasing adiponectin (but not leptin) concentrations [50]. Similar to what we observed for leptin, a borderline positive association with breast cancer risk was observed for small tumors only, which contrasts with the known anti-inflammatory properties of this adipokine [44].

Strengths of PRECAMA, the largest ongoing multicentric population-based case–control study of premenopausal breast cancer in Latin America, include the use of standardized protocols for collection of a wide range of lifestyle and anthropometric factors. We were therefore able to account for adiposity, which is strongly associated with breast cancer risk in this population [6], and other lifestyle variables, even if residual confounding cannot be entirely ruled out. The availability of centralized immunohistochemistry analyses reduced inter-laboratory variability and enabled us to stratify our analysis by breast cancer subtype. In addition, the use of a highly sensitive and specific method for measuring circulating biomarkers allowed us to measure all the cytokines of interest, even if present at very low concentrations, in all the samples in the study.

A major limitation is the case–control design of this study, that does not enable to draw any conclusion regarding the temporality of the observed associations or their potential causality. However, cases were recruited, and biological samples collected, before the start of any treatment, and tumor size was carefully recorded, which allowed us to analyze the associations accounting for disease advancement. Another limitation is that sample size was sometimes limited for subgroup analysis and resulted in limited statistical power. In addition, a total of 7 biomarkers and one ratio were analyzed overall and in stratified analyses without adjustment for multiple tests, which increases the risk of chance findings and warrants caution in the interpretation of our findings. Lastly, the generalization of these results to other age groups or geographical regions requires careful consideration.


In conclusion, this work showed that IL-6 and TNF-α are positively associated with breast cancer in premenopausal women in Latin America. While associations did not vary by hormone receptor status, except for IL-8, heterogeneity by tumor size was observed for several biomarkers (IL-8, TNF-α, leptin, adiponectin). These findings add useful information for the characterization of the obesity and metabolic health and breast cancer in premenopausal women. However, given the complex interplay between biomarkers of inflammation and cancer development, largest studies of prospective design are needed to confirm these findings in premenopausal women.


Where authors are identified as personnel of the International Agency for Research on Cancer/ World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/ World Health Organization.

Availability of data and materials

The data that support the findings of this study are available from the PRECAMA centres that provided them, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the PRECAMA Steering Committee.



Body mass index


Confidence interval


Estrogen receptor


Human epidermal growth factor receptor 2


International Agency for Research on Cancer


Interferon γ


Interleukin 6


Interleukin 8


Interleukin 10


Odds ratio


Progesterone receptor


Standard deviation


Triple negative


Tumor necrosis factor


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

    PubMed  Article  Google Scholar 

  2. Franco-Marina F, Lopez-Carrillo L, Keating NL, Arreola-Ornelas H, Marie Knaul F. Breast cancer age at diagnosis patterns in four Latin American Populations: A comparison with North American countries. Cancer Epidemiol. 2015;39(6):831–7.

    PubMed  Article  Google Scholar 

  3. Amadou A, Torres-Mejia G, Hainaut P, Romieu I. Breast cancer in Latin America: global burden, patterns, and risk factors. Salud Publica Mex. 2014;56(5):547–54.

    PubMed  Article  Google Scholar 

  4. World Cancer Research Fund International / American Institute for Cancer Research: Continuous Update Project Report: Diet, Nutrition and Physical activity and Breast Cancer. In.; 2017.

  5. Amadou A, Torres Mejia G, Fagherazzi G, Ortega C, Angeles-Llerenas A, Chajes V, Biessy C, Sighoko D, Hainaut P, Romieu I. Anthropometry, silhouette trajectory, and risk of breast cancer in Mexican women. Am J Prev Med. 2014;46(3 Suppl 1):S52-64.

    PubMed  Article  Google Scholar 

  6. His M, Biessy C, Torres-Mejia G, Angeles-Llerenas A, Alvarado-Cabrero I, Sanchez GI, Borrero M, Porras C, Rodriguez AC, Garmendia ML, et al. Anthropometry, body shape in early-life and risk of premenopausal breast cancer among Latin American women: results from the PRECAMA study. Sci Rep. 2020;10(1):2294.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. Liu B, Giffney HE, Arthur RS, Rohan TE, Dannenberg AJ. Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review. Cancer Prev Res (Phila). 2021;14(5):509–20.

    CAS  Article  Google Scholar 

  8. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno-Bueno G. Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status. Frontiers in Oncology. 2021;11:705911. eCollection 2021.

  9. Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circ Res. 2020;126(11):1549–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Brown KA. Metabolic pathways in obesity-related breast cancer. Nat Rev Endocrinol. 2021;17(6):350–63.

    PubMed  Article  CAS  Google Scholar 

  11. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-Reactive Protein and Breast Cancer Risk-Systematic Literature Review and Meta-analysis of Prospective Cohort Studies. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1439–49.

    CAS  PubMed  Article  Google Scholar 

  13. Wang G, Li N, Chang S, Bassig BA, Guo L, Ren J, Su K, Li F, Chen S, Wu S, et al. A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev. 2015;24(2):459–65.

    CAS  PubMed  Article  Google Scholar 

  14. Zhang SM, Ridker PM. Re: C-reactive protein and risk of breast cancer : Response. J Natl Cancer I. 2008;100(6):444–5.

    CAS  Article  Google Scholar 

  15. Kehm RD, McDonald JA, Fenton SE, Kavanaugh-Lynch M, Leung KA, McKenzie KE, Mandelblatt JS, Terry MB. Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research. Int J Environ Res Public Health. 2020;17(15):5445.

  16. Agnoli C, Grioni S, Pala V, Allione A, Matullo G, Gaetano CD, Tagliabue G, Sieri S, Krogh V. Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort. Sci Rep. 2017;7(1):12708.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  17. Olivier M, Bouaoun L, Villar S, Robitaille A, Cahais V, Heguy A, Byrnes G, Le Calvez-Kelm F, Torres-Mejia G, Alvarado-Cabrero I, et al. Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS ONE. 2019;14(1): e0210372.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. Romieu I, Biessy C, Carayol M, His M, Torres-Mejia G, Angeles-Llerenas A, Sanchez GI, Jaramillo R, Navarro E, Porras C, et al. Reproductive factors and molecular subtypes of breast cancer among premenopausal women in Latin America: the PRECAMA study. Sci Rep. 2018;8(1):13109.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  19. Romieu I, Biessy C, Torres-Mejia G, Angeles-Llerenas A, Sanchez GI, Borrero M, Ossa CA, Porras C, Rodriguez AC, Ocampo R, et al. Project profile: a multicenter study on breast cancer in young women in Latin America (PRECAMA study). Salud Publica Mex. 2019;61(5):601–8.

    PubMed  Article  Google Scholar 

  20. Mendy M, Caboux E, Lawlor RT, Wright J, Wild CP. Common Minimum Technical Standards and Protocols for Biobanks Dedicated to Cancer Research; 2017. Lyon (FR): International Agency for Research on Cancer; 2017. IARC Technical Publications. PMID: 33539055 Bookshelf ID: NBK567251.

  21. Vaught JB, Caboux E, Hainaut P. International efforts to develop biospecimen best practices. Cancer Epidemiol Biomarkers Prev. 2010;19(4):912–5.

    PubMed  Article  Google Scholar 

  22. Wang H, Yang X. Association between serum cytokines and progression of breast cancer in Chinese population. Medicine (Baltimore). 2017;96(49): e8840.

    CAS  Article  Google Scholar 

  23. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82–4.

    CAS  PubMed  Google Scholar 

  24. Ma YF, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu JR. IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017;26(3):421–6.

    PubMed  Article  Google Scholar 

  25. Heikkila K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008;44(7):937–45.

    CAS  PubMed  Article  Google Scholar 

  26. Dethlefsen C, Hojfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657–64.

    CAS  PubMed  Article  Google Scholar 

  27. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–48.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10(21):7157–62.

    CAS  PubMed  Article  Google Scholar 

  29. Todorovic-Rakovic N, Milovanovic J. Interleukin-8 in Breast Cancer Progression. J Interf Cytok Res. 2013;33(10):563–70.

    CAS  Article  Google Scholar 

  30. Lin Y, Huang RC, Chen LP, Li SY, Shi Q, Jordan C, Huang RP. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer. 2004;109(4):507–15.

    CAS  PubMed  Article  Google Scholar 

  31. Liu Q, Li AP, Tian YJ, Wu JD, Liu Y, Li TF, Chen Y, Han XW, Wu KM. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth F R. 2016;31:61–71.

    Article  Google Scholar 

  32. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol. 2001;158(2):639–46.

    PubMed  PubMed Central  Article  Google Scholar 

  33. Sorensen CJ, Pedersen OB, Petersen MS, Sorensen E, Kotze S, Thorner LW, Hjalgrim H, Rigas AS, Moller B, Rostgaard K, et al. Combined oral contraception and obesity are strong predictors of low-grade inflammation in healthy individuals: results from the Danish Blood Donor Study (DBDS). PLoS ONE. 2014;9(2): e88196.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  34. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Cogliano V, et al. A review of human carcinogens–Part A: pharmaceuticals. Lancet Oncol. 2009;10(1):13–4.

    PubMed  Article  Google Scholar 

  35. Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133(1):11–21.

    CAS  PubMed  Article  Google Scholar 

  36. Dai JGW, Y.F, Li M. Changes of serum tumor markers, immunoglobulins, TNF-α and hsCRP levels in patients with breast cancer and its clinical significance. J Hainan Med Univ. 2017;23(20):89–92.

    Google Scholar 

  37. Hamed EA, Zakhary MM, Maximous DW. Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer. J Cancer Res Clin Oncol. 2012;138(6):999–1009.

    CAS  PubMed  Article  Google Scholar 

  38. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat. 1997;43(3):211–5.

    CAS  PubMed  Article  Google Scholar 

  39. Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1–18.

    CAS  Article  Google Scholar 

  40. Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor alpha Blockade: An Opportunity to Tackle Breast Cancer. Front Oncol. 2020;10:584.

    PubMed  PubMed Central  Article  Google Scholar 

  41. Jorgovanovic D, Song MJ, Wang LP, Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res. 2020;8:49. eCollection 2020.

  42. Kaur RP, Vasudeva K, Singla H, Benipal RPS, Khetarpal P, Munshi A. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer. J Cell Physiol. 2018;233(12):9716–23.

    CAS  PubMed  Article  Google Scholar 

  43. Tzang BS, Chen VC, Hsieh CC, Wang WK, Weng YP, Ho HY, Hsu YT, Hsaio HP, Weng JC, Chen YL. Differential associations of proinflammatory and anti-inflammatory cytokines with depression severity from noncancer status to breast cancer course and subsequent chemotherapy. BMC Cancer. 2020;20(1):686.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer. 2021;125(4):495–509.

    PubMed  PubMed Central  Article  Google Scholar 

  45. Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, Jonsson H, Stattin P. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009;113(3):567–76.

    CAS  PubMed  Article  Google Scholar 

  46. Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res (Phila). 2011;4(9):1449–56.

    CAS  Article  Google Scholar 

  47. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O’Rahilly S, Balkau B, Flyvbjerg A, Walker M, Hojlund K, Nolan JJ, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, Hankinson SE. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510–6.

    CAS  PubMed  Article  Google Scholar 

  49. Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(4):1226–36.

    PubMed  PubMed Central  Article  Google Scholar 

  50. Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol. 2012;30(2):151–7.

    CAS  PubMed  Article  Google Scholar 

Download references


The authors wish to acknowledge the substantial support provided by the research nurses and health workers as well as Tracy Lignini, Dacia Cristin, Cecile Le Duc, Jordi de Battle, Ana Cristina Ocampo, and Dr Talita Duarte-Salles for the logistics and data basis development. The authors also thank Dr Magali Olivier for her important contribution to the study. Ana Cecilia Rodriguez was part of the Proyecto Guanacaste when this work was carried out. The authors also wish to thank the women participating in the project, for their time and commitment. **PRECAMA Team: Jenny Tejeda2, María Felix Lazcano2, Libia Zulema Franco2, Roberto Jaramillo6, Alberto Angel12, Carlos Andres Ossa13, William H. Arias14, Gabriel Bedoya14, Alicia Cock-Rada15, Carolina Echeverri15, Fernando Herazo15, Israel Díaz-Yunez16, Angel Hernández17, Bernal Cortes7, Paula Gonzalez7†, Rebecca Ocampo7, Diego Guillen7, Viviana Loría7, Catalina Vial18, Lizette Diaz18, Elizabeth Donato10, Thomas Donn10, Kelly Wirtala10, Hailey Loucks10, 12Torre Médica Las Américas, Medellín, Colombia, 13Torre Médica El Tesoro, Medellín, Colombia, 14GENMOL Group, Natural and Basic Sciences Faculty, University of Antioquia, Medellín, Colombia, 15Instituto de Cancerología Las Américas, Medellín, Colombia, 16Imágenes Diagnósticas y Biotecnología Reproductiva, Cediul S.A., Barranquilla, Colombia, 17Clínica Bonnadona Prevenir, Barranquilla, Colombia, 18National Institute of Cancer, Santiago, Chile, †Deceased.


The study is funded by the International Agency for Research on Cancer (IARC), the Union for International Cancer Control (UICC), the Pan American Health Organization (PAHO), the Ibero-American Programme for the Development of Science and Technology (CYTED), Ministerio de Ciencia, Tecnología e Innovación (Colombia, MINCIENCIAS, grant #111584267659). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations




SR, GTM, GIS, CP, ACRo, MLG, PLP, and IR designed the study. GTM, AAL, IAC, GIS, EN, YRC, CP, ACRo, MLG, LM, JLS and members of the PRECAMA team (JT, MFL, LZF, RJ, AA, CAO, WHA, GB, ACRa, CE, FH, IDY, AH, BC, PG, RO, DG, VL, CV, LD) collected the data and sample materials. PLP designed the specific protocols for IHC and genetic analyses. PLP, MGL, and JG, together with members of the PRECAMA team (ED, TD, KW, HL), conducted molecular analyses. ASN conducted the laboratory analysis of inflammation markers under supervision of SR. CB assembled the database. EF and MH analyzed the data. EF, MH, GTM, GIS, CP, ACRo, MLG, IR, and SR interpreted the data. EF, MH, and SR were responsible for drafting the manuscript. All authors provided critical interpretation of the results and review of the first draft and read and approved the final manuscript.

Corresponding author

Correspondence to Sabina Rinaldi.

Ethics declarations

Ethics approval and consent to participate

All participants gave written informed consent before enrolment, and the study protocols were approved by the institutional review boards of Chile (Oncologic Institute Foundation Arturo Lopez Pérez, Instituto de Nutrición y de Tecnología de los Alimentos, National Cancer Institute), Colombia (Cancer Institute Las Americas and University of Antioquia), Costa Rica (Costa Rican Institute of Clinical Research (ICIC) and Center for Strategic Development and Information in Health and Social Security (CENDEISSS) of the Costa Rican Social Security Fund (CCSS)), Mexico (National Institute of Public Health and the Social Security Mexican Institute), and the International Agency for Research on Cancer (IARC). All methods were performed in accordance with the Declaration of Helsinki and other relevant guidelines and regulations of these approvals.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Ana Cecilia Rodriguez was part of the Proyecto Guanacaste when this work was carried out.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Main characteristics of cases by hormone receptor status, and for triple-negative tumors (Supplementary Table 1). Associations between IL-6 and TNF-alpha and breast cancer risk allowing for non-linear effects (natural cubic splines) (Supplementary Figure 1); Abbreviations: BMI body mass index; ER Estrogen receptor; HER2 human epidermal growth factor receptor 2; IFN-γ interferon γ; IL-6 interleukin 6; IL-8 interleukin 8; IL-10 interleukin 10; OR odds ratio; PR progesterone receptor; SD standard deviation; TNF-α tumor necrosis factor α. (DOC 109 KB).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fontvieille, E., His, M., Biessy, C. et al. Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study. BMC Cancer 22, 877 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Inflammation
  • Biomarkers
  • Breast cancer
  • Premenopausal
  • Latin America